Drug General Information (ID: DDI43ZF6RA)
Drug Name			Tositumomab (I-131)		Drug Info		Clozapine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Therapeutic Radiopharmaceuticals				Antipsychotic Agents

Mechanism of Tositumomab (I-131)-Clozapine Interaction (Severity Level: Major)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Tositumomab (I-131)				Clozapine
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Tositumomab (I-131) and Clozapine

Recommended Action
Management		Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
3	Canadian Pharmacists Association "e-CPS."